Chiron Health AI

Cover Block

Name	Chiron Health AI
Tagline	AI-driven platform for personalized, evidence-based chronic disease management.
Headquarters	London, UK
Founded	2023
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Carron Manning, Davide Crescenzi, Karen Lawson
Funding Label	Pre-seed

Links

• Website: https://chironai.co
• LinkedIn: https://www.linkedin.com/company/chiron-health-ai

Summary and Signal

Chiron Health AI is building an AI-driven platform to personalize self-care for chronic disease. The company, founded in 2023 and emerging from the Founders Factory venture studio, secured a pre-seed round led by SFC Capital [StartupMag]. Its initial wedge is fibromyalgia, where the platform is recommending interventions to over a thousand users [Founders Factory, 2026] [Lucy Stirling - Chiron Health AI | LinkedIn, 2026].

The founding team combines healthcare industry expertise with product and technology clout, led by CEO Carron Manning [Founders Factory, 2026]. Their product strategy involves training proprietary algorithms on a foundational dataset to create hyper-personalized guidelines, with a roadmap to develop a B2B product for payers and providers [Chiron Health AI | F6S, 2026] [SFC Capital leads investment in health-tech startup Chiron Health AI, 2026].

Data Accuracy: YELLOW -- Core company details and funding lead are confirmed by multiple sources; specific founder backgrounds and detailed product metrics are less extensively documented in public primary sources.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Western Europe
Growth Profile	Venture Scale
Funding	Pre-seed

Company Overview

Chiron Health AI was founded in 2023 as a venture studio company within the Founders Factory ecosystem [UK Tech Investment News by Deal Lite, 2024], [Founders Factory, 2026]. The company is headquartered in London, UK, and operates in the business-to-consumer healthtech sector.

In 2024, the company secured a place on the DigitalHealth.London Launchpad programme [DigitalHealth.London]. Later that year, it closed a pre-seed funding round led by SFC Capital [UK Tech Investment News by Deal Lite, 2024], [Crunchbase, 2026]. By 2026, the company reported that over 1,000 people with chronic pain had gained exclusive access to its platform [Lucy Stirling - Chiron Health AI | LinkedIn, 2026].

Data Accuracy: YELLOW -- Founding date, accelerator participation, and investor lead are confirmed by multiple sources. The user traction figure is a single, self-reported metric.

The Product and the Stack

The product is an AI-driven platform designed to manage chronic disease through personalized, evidence-based self-care, focusing initially on fibromyalgia [Founders Factory, 2026]. The platform's core function is to match individual patient profiles to interventions with a high likelihood of clinical effectiveness [Perplexity Sonar Pro Brief].

Technically, the system relies on AI algorithms trained on a proprietary data foundation to generate hyper-personalised self-care guidelines [Chiron Health AI | F6S, 2026]. The business model is currently B2C, providing this service to over 1,000 people with chronic pain [Lucy Stirling - Chiron Health AI | LinkedIn, 2026]. A significant roadmap item is the launch of a fully integrated B2B product aimed at healthcare payers, providers, and pharmaceutical companies [SFC Capital leads investment in health-tech startup Chiron Health AI, 2026].

Data Accuracy: YELLOW -- Core product claims are consistent across multiple sources, but technical implementation details are not publicly disclosed.

The Market They Are Entering

Chronic disease management is a high-cost problem for healthcare systems. The global market for digital therapeutics was valued at $4.5 billion in 2022 and is projected to grow at a compound annual rate of 26.1% through 2030 [Grand View Research, 2023]. The economic burden of chronic pain in the UK is estimated to exceed £10 billion annually [British Pain Society, 2021].

Metric	Value
Digital Therapeutics (Global, 2022)	4.5 $B
Projected CAGR (2023-2030)	26.1 %
UK Chronic Pain Economic Burden	10 £B

Data Accuracy: YELLOW -- Market sizing figures are from third-party reports for analogous sectors; Chiron-specific segmentation is not publicly available.

The Competitive Field

Chiron Health AI enters a fragmented market for chronic disease management. The competitive map includes established digital therapeutics platforms like Omada Health and Livongo, condition-specific apps, and emerging AI-native health recommendation engines.

Chiron's edge rests on its proprietary data foundation and institutional backing [Chiron Health AI | F6S, 2026]. Emerging from the Founders Factory venture studio and securing backing from SFC Capital provides credibility and potential network access within the UK's DigitalHealth.London ecosystem [UK Tech News, 2024]. The company's most significant exposure is its lack of a proven commercial channel and the high regulatory and evidence bar for clinical adoption.

Data Accuracy: YELLOW -- Competitive analysis is based on public positioning of named market segments; specific competitor funding and differentiation are inferred from general market knowledge.

Opportunity

Chiron Health AI aims to become the default, evidence-based self-care layer integrated into standard chronic disease management pathways. The initial focus on fibromyalgia is a strategic wedge into a high-need segment [Founders Factory, 2026].

Scenario	What happens	Catalyst
B2B Payer Adoption	Chiron's platform is adopted by national health services or private insurers as a covered benefit.	The launch of its fully integrated B2B product [SFC Capital leads investment in health-tech startup Chiron Health AI, 2026].
Pharma Partnership & Integration	A pharmaceutical company licenses Chiron's self-care pathway to improve patient adherence.	Successful pilot data showing the platform improves medication adherence or quality-of-life scores.

Data Accuracy: YELLOW -- Core opportunity thesis is built from company and investor statements; early user traction is cited from a company LinkedIn post.

Sources

1. [StartupMag] Chiron Health AI Revolutionizes Chronic Disease Management | https://www.startupmag.co.uk/funding/chiron-health-ai-raised/
2. [Founders Factory, 2026] Founders Factory | https://foundersfactory.com/
3. [Lucy Stirling - Chiron Health AI | LinkedIn, 2026] Lucy Stirling - Chiron Health AI | LinkedIn | https://www.linkedin.com/in/lucy-stirling-bb7973b3/
4. [UK Tech Investment News by Deal Lite, 2024] UK Tech Investment News by Deal Lite | https://uktechinvestmentnews.com/
5. [Crunchbase, 2026] Chiron - 2026 Company Profile, Team & Competitors - Tracxn | https://tracxn.com/d/companies/chiron/__6Y1qdd27YR3aeXcryoX80oATigWE3sghvxBvmTtsYtA
6. [Chiron Health AI | F6S, 2026] Chiron Health AI | F6S | https://www.f6s.com/company/chiron-health-ai
7. [SFC Capital leads investment in health-tech startup Chiron Health AI, 2026] SFC Capital leads investment in health-tech startup Chiron Health AI | https://www.sfccapital.com/
8. [Grand View Research, 2023] Digital Therapeutics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/digital-therapeutics-market
9. [British Pain Society, 2021] The British Pain Society | https://www.britishpainsociety.org/
10. [DigitalHealth.London] DigitalHealth.London Launchpad | https://digitalhealth.london/launchpad/